Dr. Markus Zimmer is Co-CEO of Ketabon, together with Dr. Maximilian Döbler.
Besides his responsibilities at Ketabon, Markus is also Member of the Board of Directors at Develco Pharma and Helmadis – both founding partners of Ketabon. Prior to this, Markus served as Member of the Board of Directors and COO at Algobate and founded as well as headed YES Pharma Services, today known as PharmaLex.
Markus holds a PhD in Pharmaceutical Sciences.
Together with Dr. Markus Zimmer, Dr. Maximilian Döbler as Co-CEO is responsible for all business and corporate development activities at Ketabon. He focuses on the company’s partnership agreements and strategy development, including potential deals and cooperations. Furthermore, Maximilian coordinates the company’s marketing and communication activities.
Besides his responsibilities at Ketabon, Maximilian is Chief Business Officer at HMNC Brain Health – one of Ketabon’s founding partners. Prior to his time at HMNC Brain Health and Ketabon, he worked in various roles for KPMG and the Maschmeyer Group.
Maximilian holds a Doctor of Laws from the University of Salzburg.
Dr. Hans Eriksson has more than 20 years of experience in clinical development of therapeutics for psychiatric indications. As Chief Medical Officer at Ketabon he leads the clinical programs, ensuring that the strategies are aligned with the promises of the compounds in development.
Besides his responsibilities at Ketabon, Hans is Chief Medical Officer at HMNC Brain Health – one of Ketabon’s founding partners. Prior to this, Hans has held several senior clinical development roles in the pharmaceutical industry, in Sweden, Denmark, USA, and the UK. He also served as Consultant Psychiatrist and Assisting Head of the Psychiatric Clinic at Lund University Hospital.
Hans holds a MD and PhD in Cell and Molecular Biology from Lund University as well as an Executive MBA from Stockholm School of Economics.